Novartis AG ADR (NVS)vsVeru Inc (VERU)
NVS
Novartis AG ADR
$147.85
+3.44%
HEALTHCARE · Cap: $282.11B
VERU
Veru Inc
$2.25
+0.45%
HEALTHCARE · Cap: $36.76M
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 334951% more annual revenue ($56.58B vs $16.89M). NVS leads profitability with a 23.9% profit margin vs 0.0%. NVS appears more attractively valued with a PEG of 2.48. NVS earns a higher WallStSmart Score of 51/100 (C-).
NVS
Buy51
out of 100
Grade: C-
VERU
Hold41
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-52.5%
Fair Value
$109.60
Current Price
$147.85
$38.25 premium
Margin of Safety
+36.0%
Fair Value
$3.50
Current Price
$2.25
$1.25 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 30.5%
Keeps 24 of every $100 in revenue as profit
Generating 2.9B in free cash flow
Reasonable price relative to book value
18.3% revenue growth
Areas to Watch
Expensive relative to growth rate
Grey zone — moderate risk
Revenue declined 0.7%
Earnings declined 9.3%
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Operating margin of 0.0%
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.
Bull Case : VERU
The strongest argument for VERU centers on Price/Book, Revenue Growth. Revenue growth of 18.3% demonstrates continued momentum.
Bear Case : NVS
The primary concerns for NVS are PEG Ratio, Altman Z-Score, Revenue Growth.
Bear Case : VERU
The primary concerns for VERU are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
NVS profiles as a declining stock while VERU is a growth play — different risk/reward profiles.
NVS carries more volatility with a beta of 0.52 — expect wider price swings.
VERU is growing revenue faster at 18.3% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (51/100 vs 41/100), backed by strong 23.9% margins. VERU offers better value entry with a 36.0% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Veru Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Veru Inc., an oncology biopharmaceutical company, focuses on the development of drugs for the treatment of cancers. The company is headquartered in Miami, Florida.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?